- Included are drugs formulated to treat Alzheimer’s, Parkinson’s, eating disorders and seizures
- IGC already has seven provisional filings for phytocannabinoid-based combination therapies
- Company also has in its pipeline combination therapy drug candidates for the treatment of end points of Parkinson’s, as well as epilepsy in cats and dogs
India Globalization Capital, Inc. (NYSE American: IGC) anticipates filing, in 2018 and 2019, for international Patent Cooperation Treaty (“PCT”) patents, as well as U.S. national patent filings, for a portfolio of drugs (http://cnw.fm/uc3XT).
Its drug for the treatment of Alzheimer’s (IGC-AD1) is anticipated for patent filings in PCT and the U.S. in 2018. Its seizure drug (IGC-505) is scheduled for filing for a U.S. patent in late 2018. The company’s eating disorders drug (IGC-504) is anticipated for filing for a U.S. patent late this year, while another eating disorders drug (IGC-506) is anticipated for filing for a PCT patent in 2018 and a U.S. filing in 2019. This portfolio encompasses the company’s drugs that are formulated to treat seizures, Alzheimer’s and eating disorders — representing large domestic and international markets.
For its drug formulated to treat Alzheimer’s, as described in a SeeThruEquity update on IGC (http://cnw.fm/wYp3F), it has formulated a cannabis-based combination which treats endpoints of the disease such as plaques, tangles, anxiety and agitation. IGC plans to market its patent-pending drug through U.S. and Canadian medical dispensaries in early 2018. A key goal for the company in 2018 is to get its lead product formulation, Hyalolex, ready for phase IIB human trials. IGC estimates that Alzheimer’s disease costs the U.S. economy alone roughly $236 billion annually. It affects more than 5.3 million Americans, and more than 65 percent of its patients are women.
IGC is a Maryland-based company with two lines of businesses. One is legacy, which includes the rental of heavy equipment, real estate management and commodities trading. The second is canna-pharmaceutical. That business is focused on developing a formulation using cannabis extracts for the treatment of many diseases.
For more information, visit the company’s website at www.IGCInc.us
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com